What tirzepatide is
Tirzepatide is a medication that acts on two of the hormone signals your body uses to regulate appetite and blood sugar. According to the FDA-approved prescribing information for Zepbound®, tirzepatide is a GIP receptor and GLP-1 receptor agonist that selectively binds to and activates both the GIP and GLP-1 receptors, the targets for the body’s own GIP and GLP-1. The same label describes GLP-1 as a physiological regulator of appetite and caloric intake, notes that nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake, and states that both receptors are found in areas of the brain involved in appetite regulation.
That two receptor action is what people mean when they call tirzepatide a dual agonist. Semaglutide, the other medication Bodi Envi’s programs are built around, acts on the GLP-1 receptor alone. The Zepbound® label also notes that tirzepatide contains a C20 fatty diacid that lets it bind to albumin in the blood and prolongs its half-life, which is why it is taken once a week rather than every day.
Tirzepatide is the active ingredient in two FDA-approved products from the same manufacturer. Zepbound® is indicated, per its label, to reduce excess body weight and maintain weight reduction long term in adults with obesity and in adults with overweight who have at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro® is indicated, per its own prescribing information, to improve blood sugar control in adults with type 2 diabetes. Brand names are trademarks of their respective owners, and Bodi Envi is not affiliated with them.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What “compounded” means
Compounding is an established part of pharmacy practice with a specific legal meaning. The FDA’s human drug compounding page defines it as the practice in which a licensed pharmacist, a licensed physician, or in the case of an outsourcing facility a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.
Personalized Compounded tirzepatide is tirzepatide prepared by a compounding pharmacy for one patient, on that patient’s prescription, rather than a finished product from the manufacturer’s line. It typically comes as a vial of solution that you draw up with a syringe rather than a pre-filled pen.
What compounding does not mean is the part to hold onto. The FDA states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. That is the central difference between a compounded medication and a branded one.
Who prepares personalized compounded tirzepatide and under what rules
Two kinds of facilities may compound drugs in the United States, and they are regulated differently. The FDA’s compounding questions and answers page explains that state-licensed pharmacies that are not registered as outsourcing facilities, commonly called 503A pharmacies after the section of the law that covers them, are overseen day to day by state boards of pharmacy. Facilities that register with the FDA as outsourcing facilities under section 503B are primarily overseen and inspected by the FDA on a risk-based schedule, and the drugs they compound are subject to current good manufacturing practice requirements, which drugs from a 503A pharmacy are not.
A 503A pharmacy compounds in response to a prescription for an identified individual patient. That patient-specific prescription is the foundation of the arrangement: a licensed provider evaluates you, decides that treatment is appropriate, writes the prescription, and the pharmacy prepares the medication for you on that basis.
Bodi Envi’s prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies. As Bodi Envi publishes in its own machine readable reference, applicable state boards of pharmacy regulate and inspect 503A compounding pharmacies, and pharmacy operations and sterile compounding practices are subject to applicable U.S. Pharmacopeia standards. VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions, and pharmacy availability may vary by program and patient location.
How it differs from Zepbound® and Mounjaro®
The shorthand “generic Mounjaro®” that people sometimes use is wrong on every count, so the differences are stated one at a time.
Personalized Compounded tirzepatide is not a generic. A generic drug is an FDA-approved copy of a brand name drug that the agency has found to be equivalent. No generic tirzepatide has been approved. A compounded product has not been through that review at all.
Personalized Compounded tirzepatide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Zepbound® and Mounjaro® went through the full approval process, including the trial described later in this guide.
Personalized Compounded tirzepatide is not equivalent to the approved products. Bodi Envi states this directly: compounded personalized tirzepatide is not FDA-approved and is not equivalent to FDA-approved products. The formulation, the concentration, the container and the quality controls differ from the branded product, and no one has run the trials that would show the two behave the same way.
What they share is the active ingredient. A provider who prescribes personalized compounded tirzepatide is prescribing the same molecule the branded products contain, prepared in a different way under a different regulatory framework, at a different price. Whether that trade is right for you is a clinical judgment, and it is the provider’s to make.
How it is taken
Tirzepatide is injected subcutaneously, into the fatty tissue just under the skin, once a week. The Zepbound® prescribing information directs patients to inject in the abdomen or thigh, or, when another person gives the injection, the back of the upper arm, and to rotate injection sites with each dose.
Dosing for the approved product follows steps. The Zepbound® label sets a starting dose of 2.5 mg once weekly for four weeks, then allows the dose to increase in 2.5 mg increments after at least four weeks on the current dose. It lists 5 mg, 10 mg and 15 mg as the maintenance doses and 15 mg once weekly as the maximum. The label describes the 2.5 mg dose as a starting dose for treatment initiation, not a maintenance dose.
With a compounded prescription, that schedule is a reference, not a rule. Your provider sets your starting dose, decides when and whether to increase it, and can hold or lower a dose if you are not tolerating it. Bodi Envi’s pricing does not increase based solely on dosage strength, so the dose decision is a clinical one rather than a financial one. Follow your provider’s plan and the pharmacy’s measuring instructions, and ask before changing anything.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the research on tirzepatide shows
The headline study for tirzepatide in weight management is the SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022 by Jastreboff and colleagues. According to the abstract on PubMed, the trial enrolled 2,539 adults with a body mass index of 30 or more, or 27 or more with at least one weight-related complication, excluding people with diabetes. They were assigned to once weekly tirzepatide at 5 mg, 10 mg or 15 mg, or to placebo, for 72 weeks including a 20 week dose escalation period.
The mean percentage change in weight at week 72 was 15.0 percent with 5 mg, 19.5 percent with 10 mg and 20.9 percent with 15 mg, against 3.1 percent with placebo. The share of participants who lost 5 percent or more of their body weight was 85 percent, 89 percent and 91 percent for the three doses and 35 percent with placebo, and half or more of the participants in the 10 mg and 15 mg groups lost 20 percent or more. The most common adverse events were gastrointestinal, most were mild to moderate, and they occurred primarily during dose escalation. Adverse events led to discontinuation in 4.3 percent, 7.1 percent and 6.2 percent of the three tirzepatide groups and 2.6 percent of the placebo group.
Two caveats belong next to those numbers. First, SURMOUNT-1 studied Zepbound®, the branded product, at its approved doses, and not a compounded version. No trial of that size has been run on personalized compounded tirzepatide, and results from the branded product cannot simply be assumed to carry over. Second, a trial average is not a promise. Your own result depends on your dose, how long you stay on treatment, what you eat, how you move and factors nobody can predict. Individual experiences and outcomes vary.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Who may be a candidate
A licensed healthcare provider determines whether treatment is appropriate for each individual patient. That is Bodi Envi’s own published position and it is the honest answer.
In broad terms, the approved product is indicated for adults with obesity and for adults with overweight who have a weight-related condition, and SURMOUNT-1 enrolled people in that range. A provider will also look at what could make treatment unsafe for you. The Zepbound® label lists a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 as a contraindication, along with a known serious hypersensitivity to tirzepatide, and it carries warnings about severe gastrointestinal reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, low blood sugar when combined with certain diabetes medications, and several other conditions. The safety guide on this site goes through those warnings in detail.
Your assessment asks about all of this so the provider has what they need. Answer it completely; a provider who does not know about a medication you take or a condition in your family cannot make a safe decision.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How the Bodi Envi program works
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer, and it does not compound anything itself.
The program has three parts. You complete an online health assessment from any device. A licensed provider, through Wasef Health, PC for applicable programs, reviews your answers and decides whether personalized compounded tirzepatide is appropriate for you. If it is, the prescription goes to VialsRx, the current pharmacy partner for applicable GLP-1 prescriptions, which prepares and ships your medication.
Pricing is published on the Plans page and is the same at every dose. The personalized compounded tirzepatide program is $229 per month billed monthly, or $219, $205 and $175 per month on prepaid three, six and twelve month terms. The price includes the assessment, provider review, messaging with your care team, a GLP-1 ebook and diet plan, and the medication when it is prescribed. Medication is included only when a licensed healthcare provider determines treatment is medically appropriate and issues a prescription, and paying for a program does not guarantee one. The tirzepatide cost guide on this site compares these figures with the brand list prices and the manufacturer’s self pay vials.